» Articles » PMID: 29109725

Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An Analysis of Immune Recruitment and Cytokine Release

Overview
Journal Front Immunol
Date 2017 Nov 8
PMID 29109725
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

In a previous work, we showed that CSF-470 vaccine plus bacillus Calmette-Guerin (BCG) and granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvants resulted in a significant benefit in the distant metastasis-free survival when comparing vaccinated . IFN-α2b-treated high-risk cutaneous melanoma patients in a Phase II study. Immune monitoring demonstrated an increase in anti-tumor innate and adaptive immunities of vaccinated patients, with a striking increase in IFN-γ secreting lymphocytes specific for melanoma antigens (Ags). In an effort to dissect the first steps of the immune response elicited by CSF-470 vaccine plus adjuvants, we evaluated, in an model, leukocyte migration, cytokine production, and monocyte phagocytosis of vaccine cells. Our results demonstrate that leukocytes recruitment, mostly from the innate immune system, is an early event after CSF-470 vaccine plus BCG plus GM-CSF interaction with immune cells, possibly explained by the high expression of CCL2/MCP-1 and other chemokines by vaccine cells. Early release of TNF-α and IL-1β pro-inflammatory cytokines and efficient tumor Ags phagocytosis by monocytes take place and would probably create a favorable context for Ag processing and presentation. Although the presence of the vaccine cells hampered cytokines production stimulated by BCG in a mechanism partially mediated by TGF-β and IL-10, still significant levels of TNF-α and IL-1β could be detected. Thus, BCG was required to induce local inflammation in the presence of CSF-470 vaccine cells.

Citing Articles

VACCIMEL, an allogeneic melanoma vaccine, efficiently triggers T cell immune responses against neoantigens and alloantigens, as well as against tumor-associated antigens.

Carri I, Schwab E, Trivino J, von Euw E, Nielsen M, Mordoh J Front Immunol. 2025; 15():1496204.

PMID: 39840067 PMC: 11747570. DOI: 10.3389/fimmu.2024.1496204.


Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCRβ Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood.

Aris M, Bravo A, Garcia Alvarez H, Carri I, Podaza E, Blanco P Front Immunol. 2019; 10:2213.

PMID: 31620131 PMC: 6759869. DOI: 10.3389/fimmu.2019.02213.


Dissecting the Immune Stimulation Promoted by CSF-470 Vaccine Plus Adjuvants in Cutaneous Melanoma Patients: Long Term Antitumor Immunity and Short Term Release of Acute Inflammatory Reactants.

Pampena M, Cartar H, Cueto G, Levy E, Blanco P, Barrio M Front Immunol. 2018; 9:2531.

PMID: 30450100 PMC: 6224428. DOI: 10.3389/fimmu.2018.02531.

References
1.
Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

2.
Distler J, Schett G, Gay S, Distler O . The controversial role of tumor necrosis factor alpha in fibrotic diseases. Arthritis Rheum. 2008; 58(8):2228-35. DOI: 10.1002/art.23645. View

3.
Palframan R, Jung S, Cheng G, Weninger W, Luo Y, Dorf M . Inflammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inflamed tissues. J Exp Med. 2001; 194(9):1361-73. PMC: 2195988. DOI: 10.1084/jem.194.9.1361. View

4.
Slingluff Jr C, Petroni G, Olson W, Czarkowski A, Grosh W, Smolkin M . Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008; 26(30):4973-80. PMC: 2652084. DOI: 10.1200/JCO.2008.17.3161. View

5.
Wong K, Yeap W, Tai J, Ong S, Dang T, Wong S . The three human monocyte subsets: implications for health and disease. Immunol Res. 2012; 53(1-3):41-57. DOI: 10.1007/s12026-012-8297-3. View